AVSTERA THERAPEUTICS
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients. Founded in 2021, with a focus on foundational science, Avstera leverages cutting edge approaches to tackle key immunological challenges seen in the tumor microenvironment. Avstera also is proud to be collaborating with top cancer researchers at both Georgetown University and the University of Pennsylvania.
AVSTERA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Oncology Therapeutics
Founded:
2021-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.avstera.com
Total Employee:
1+
Status:
Active
Contact:
+2679250452
Email Addresses:
[email protected]
Total Funding:
9.55 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Google Font API Google Tag Manager WordPress Google Analytics Font Awesome Global Site Tag Google Analytics 4
Similar Organizations
BeiGene
BeiGene is a global oncology company.
Celsius Therapeutics
Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.
IDEAYA Biosciences
IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Myricx Pharma
Myricx Pharma is a drug discovery company focused on developing small molecule inhibitors.
Scorpion Therapeutics
Scorpion Therapeutics is a precision oncology company that broadens the reach and impact of precision medicine for cancer patients.
Sword Health
Sword Health offers digital physical therapy programs with AI coaching to help people recover from pain and avoid surgery.
Thyme Care
Thyme Care is a Nashville TN-based provider of oncology care management solutions.
Valneva
Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.
Current Employees Featured
Founder
Official Site Inspections
http://www.avstera.com Semrush global rank: 11.51 M Semrush visits lastest month: 157
- Host name: 210.193.145.34.bc.googleusercontent.com
- IP address: 34.145.193.210
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Avstera Therapeutics"
Avstera
At Avstera, our primary initial focus is to address the significant unmet need of advanced cancer patients who have limited or no treatment options. These include patients who fail to respond …See details»
About Us - Avstera
Avstera Therapeutics is an oncology-focused biotech company located in the Philadelphia area dedicated to address the large disease burden and significant unmet need of advanced cancer patients. With a focus on foundational tumor …See details»
Avstera Therapeutics - Crunchbase Company Profile & Funding
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients. Founded in 2021, with a focus on foundational science, Avstera leverages cutting …See details»
Avstera Therapeutics Company Profile 2024: Valuation, …
Avstera Therapeutics was founded in 2020. Where is Avstera Therapeutics headquartered? Avstera Therapeutics is headquartered in Malvern, PA. What is the size of Avstera Therapeutics? Avstera Therapeutics has 6 total …See details»
Avstera Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Oct 2, 2023: Seed Round - …See details»
Avstera Therapeutics Corp. - BIO International Convention | BIO
Jun 7, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... At Avstera, …See details»
Avstera Therapeutics Corp. - BIO CEO & Investor Conference | BIO
Feb 7, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... At Avstera, …See details»
Newsroom - Avstera
Nov 9, 2022 Avstera Therapeutics Receives FDA Orphan Drug Designation on AVS100 for Treatment of Advanced Stage Melanoma. November 9, 2022 Avstera Therapeutics Closes …See details»
Avstera Therapeutics Closes Seed Round to Advance its Lead …
Nov 9, 2022 $4.55M Seed round with participation from a consortium of pharma and biotech investors, founded by Karthik Musunuri and Ajay Raju. PHILADELPHIA, Nov. 9, 2022 …See details»
FDA Grants Orphan Drug Designation to AVS100 for …
Nov 17, 2022 Avstera Therapeutics Receives FDA Orphan Drug Designation on AVS100 for Treatment of Advanced Stage Melanoma. News release. Avstera Therapeutics. November 11, 2022. Accessed November 17, 2022.See details»
Avstera Therapeutics Announces FDA Clearance of IND …
Dec 18, 2023 Avstera intends to initiate the Phase Ia/b clinical trial in the first half of 2024. The principal investigator of the study is Apostolia M Tsimberidou, MD, PhD, FASCO, FAAAS, …See details»
Avstera Therapeutics Closes Seed Round to Advance its Lead …
Nov 9, 2022 Avstera Therapeutics Corp., a biotechnology company based in the Philadelphia area, has announced the completion of its seed round to advance its lead cancer programs …See details»
Avstera Therapeutics Announces FDA Clearance of IND …
Dec 18, 2023 Avstera Therapeutics Corp, an oncology-focused biotech dedicated to addressing the large disease burden and significant unmet need of cancer patients, today announced the …See details»
Avstera Therapeutics Closes Seed Round to Advance its Lead …
Nov 9, 2022 $4.55M Seed round with participation from a consortium of pharma and biotech investors, founded by Karthik Musunuri and Ajay Raju.. PHILADELPHIA, Nov. 9, 2022 …See details»
Avstera Therapeutics Receives FDA Orphan Drug Designation on …
Nov 11, 2022 Avstera Therapeutics Corp, an oncology-focused biotech dedicated to address the large disease burden and significant unmet need of cancer patients, has announced that the …See details»
Avstera Therapeutics Receives FDA Orphan Drug Designation on …
PHILADELPHIA, Nov. 11, 2022 /PRNewswire/ -- Avstera Therapeutics Corp, an oncology-focused biotech dedicated to address the large disease burden and significant unmet need of cancer …See details»
Avstera’s AVS-100 cleared to enter clinic for solid tumors
Avstera Therapeutics Corp. has received FDA clearance of its IND application for HDAC6 inhibitor AVS-100. Avstera intends to initiate a phase Ia/b trial in the first half of 2024 to evaluate AVS …See details»
Avstera Therapeutics Receives FDA Orphan Drug Designation on …
PHILADELPHIA, Nov. 11, 2022 /PRNewswire/ — Avstera Therapeutics Corp, an oncology-focused biotech dedicated to address the large disease burden and significant unmet need of …See details»
Pipeline - Avstera
Avstera intends to initiate this clinical study in the first half of 2024. AVS200 (Cell Therapy) AVS200 is Avstera’s first-in-class myeloid cell therapy platform. Avstera intends to advance a …See details»
Astra Organisation | Leading Sales and Marketing Company
“If your actions inspire others to dream more, learn more, do more and become more, you are a leader.” — John Quincy AdamsSee details»